205 related articles for article (PubMed ID: 19223535)
1. Enhanced immune recognition of cryptic glycan markers in human tumors.
Newsom-Davis TE; Wang D; Steinman L; Chen PF; Wang LX; Simon AK; Screaton GR
Cancer Res; 2009 Mar; 69(5):2018-25. PubMed ID: 19223535
[TBL] [Abstract][Full Text] [Related]
2. Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.
Simon AK; Newsom-Davis T; Frayne ME; Ch'en PF; McMichael AJ; Screaton GR
Int Immunol; 2008 Apr; 20(4):525-34. PubMed ID: 18310066
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.
Hakomori S
Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):89-100. PubMed ID: 34161162
[TBL] [Abstract][Full Text] [Related]
5. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.
Loureiro LR; Sousa DP; Ferreira D; Chai W; Lima L; Pereira C; Lopes CB; Correia VG; Silva LM; Li C; Santos LL; Ferreira JA; Barbas A; Palma AS; Novo C; Videira PA
Sci Rep; 2018 Aug; 8(1):12196. PubMed ID: 30111774
[TBL] [Abstract][Full Text] [Related]
6. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation.
Meichenin M; Rocher J; Galanina O; Bovin N; Nifantev N; Sherman A; Cassagnau E; Heymann MF; Bara J; Fraser RH; Le Pendu J
Cancer Res; 2000 Oct; 60(19):5499-507. PubMed ID: 11034094
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand DNA enhances a vaccination effect by coadministered DNA encoding a tumor antigen through augmenting production of antibody against the tumor antigen.
Zhong B; Ma G; Sato A; Shimozato O; Liu H; Li Q; Shingyoji M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
J Immunol Res; 2015; 2015():743828. PubMed ID: 25759847
[TBL] [Abstract][Full Text] [Related]
8. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
9. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
Soong RS; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
PLoS One; 2013; 8(2):e56912. PubMed ID: 23457640
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
12. Glycans as targets for therapeutic antitumor antibodies.
Rabu C; McIntosh R; Jurasova Z; Durrant L
Future Oncol; 2012 Aug; 8(8):943-60. PubMed ID: 22894669
[TBL] [Abstract][Full Text] [Related]
13. Protective, anti-tumor monoclonal antibody recognizes a conformational epitope similar to melibiose at the surface of invasive murine melanoma cells.
Dobroff AS; Rodrigues EG; Moraes JZ; Travassos LR
Hybrid Hybridomics; 2002 Oct; 21(5):321-31. PubMed ID: 12470474
[TBL] [Abstract][Full Text] [Related]
14. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
[TBL] [Abstract][Full Text] [Related]
16. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
17. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
[TBL] [Abstract][Full Text] [Related]
19. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.
Jodo S; Hohlbaum AM; Xiao S; Chan D; Strehlow D; Sherr DH; Marshak-Rothstein A; Ju ST
J Immunol; 2000 Nov; 165(10):5487-94. PubMed ID: 11067901
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
